Toxicity Evaluation of Statin Group Drugs Using in Silico Methods

Year 2024, Volume: 28 Issue: 6, 1217 - 1231

Ahmet Ali Berber , Sinem Öztürk , Murat Ömeroğlu

https://doi.org/10.16984/saufenbilder.1477253

Abstract

Cardiovascular diseases (CVDs) remain a leading cause of mortality in modern society, with factors such as sedentary lifestyles, unhealthy diets, and obesity contributing to their increasing prevalence. The widespread use of Statins for lipid-lowering therapy in both primary and secondary cardiovascular prevention is anticipated to rise in response to this trend. Given the rapid escalation in the prevalence of Statin usage, it is imperative to understand their toxicological effects on public health. While previous studies have explored various pharmacological effects of statins, comprehensive investigations into their genotoxic and Mutagenic potential are lacking. In this study, we conducted a comprehensive In silico evaluation of Statins using four different toxicological assessment programs, focusing on various genotoxicity, carcinogenicity, Mutagenicity, and Micronucleus formation endpoints. By comparing program outputs with experimental data, we assessed the reliability of In silico Toxicity predictions and discussed the consistency among different platforms. Our findings suggest discrepancies among the predictions of different programs, highlighting the importance of integrating multiple sources of data and methodologies in Toxicity evaluations. Despite inconsistencies, integrating in silico predictions with future in vitro and in vivo studies can contribute to a better understanding of the toxicological properties of statins and ensure their safe usage. This study underscores the necessity of careful evaluation and utilization of multiple data sources in decision-making regarding the toxicological profile of statins. Ultimately, leveraging in silico methods to guide future comprehensive toxicological studies will enhance our understanding of Statins' safety profiles and contribute to public health research.

Keywords

Cariovascular diseases, Statins In silico, Toxicity, Micronucleus, Mutagenicity

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• World Heart Federation, (2023). World Heart Report 2023: Confronting the World’s Number One Killer [Online]. Available: https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf
• R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, R. Aggarwal, S. Y. Ahn, M. Alvarado, H. R. Anderson, L. M. Anderson, K. G. Andrews, C. Atkinson, L. M. Baddour, S. Barker-Collo, D. H. Bartels, M. L. Bell, E. J. Benjamin, D. Bennett, K. Bhalla, B. Bikbov, A. Bin Abdulhak, G. Birbeck, F. Blyth, I. Bolliger, S. Boufous, C. Bucello, M. Burch, P. Burney, J. Carapetis, H. Chen, D. Chou, S. S. Chugh, L. E. Coffeng, S. D. Colan, S. Colquhoun, K. E. Colson, J. Condon, M. D. Connor, L. T. Cooper, M. Corriere, M. Cortinovis, K. C. de Vaccaro, W. Couser, B. C. Cowie, M. H. Criqui, K. C. Dabhadkar, N. Dahodwala, D. De Leo, L. Degenhardt, A. Delossantos, J. Denenberg, D. C. Des Jarlais, S. D. Dharmaratne, E. R. Dorsey, T. Driscoll, H. Duber, B. Ebel, P. J. Erwin, P. Espindola, M. Ezzati, V. Feigin, A. D. Flaxman, M. H. Forouzanfar, F. G. Fowkes, R. Franklin, M. Fransen, M. K. Freeman, S. E. Gabriel, E. Gakidou, F. Gaspari, R. F. Gillum, D. Gonzalez-Medina, Y. A. Halasa, D. Haring, J. E. Harrison, R. Havmoeller, R. J. Hay, B. Hoen, P. J. Hotez, D. Hoy, K. H. Jacobsen, S. L. James, R. Jasrasaria, S. Jayaraman, N. Johns, G. Karthikeyan, N. Kassebaum, A. Keren, J. P. Khoo, L. M. Knowlton, O. Kobusingye, A. Koranteng, R. Krishnamurthi, M. Lipnick, S. E. Lipshultz, S. L. Ohno, J. Mabweijano, M. F. MacIntyre, L. Mallinger, L. March, G. B. Marks, R. Marks, A. Matsumori, R. Matzopoulos, B. M. Mayosi, J. H. McAnulty, M. M. McDermott, J. McGrath, G. A. Mensah, T. R. Merriman, C. Michaud, M. Miller, T. R. Miller, C. Mock, A. O. Mocumbi, A. A. Mokdad, A. Moran, K. Mulholland, M. N. Nair, L. Naldi, K. M. Narayan, K. Nasseri, P. Norman, M. O'Donnell, S. B. Omer, K. Ortblad, R. Osborne, D. Ozgediz, B. Pahari, J. D. Pandian, A. P. Rivero, R. P. Padilla, F. Perez-Ruiz, N. Perico, D. Phillips, K. Pierce, C. A. Pope III, E. Porrini, F. Pourmalek, M. Raju, D. Ranganathan, J. T. Rehm, D. B. Rein, G. Remuzzi, F. P. Rivara, T. Roberts, F. R. De León, L. C. Rosenfeld, L. Rushton, R. L. Sacco, J. A. Salomon, U. Sampson, E. Sanman, D. C. Schwebel, M. Segui-Gomez, D. S. Shepard, D. Singh, J. Singleton, K. Sliwa, E. Smith, A. Steer, J. A. Taylor, B. Thomas, I. M. Tleyjeh, J. A. Towbin, T. Truelsen, E. A. Undurraga, N. Venketasubramanian, L. Vijayakumar, T. Vos, G. R. Wagner, M. Wang, W. Wang, K. Watt, M. A. Weinstock, R. Weintraub, J. D. Wilkinson, A. D. Woolf, S. Wulf, P. H. Yeh, P. Yip, A. Zabetian, Z. J. Zheng, A. D. Lopez, C. J. Murray, M. A. AlMazroa, Z. A. Memish, “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2095-2128, 2012.
• E. E. A. Egom, H. Hafeez, “Biochemistry of Statins,” Advances in Clinical Chemistry, vol. 73, pp. 127–168, 2016.
• A. Endo, “The origin of the statins,” International Congress Series, vol. 1262, pp. 3–8, 2004.
• J. M. McKenney, P. Ganz, B. S. Wiggins, J. S. Saseen, “Statins,” Clinical lipidology: a companion to Braunwald's Heart Disease, First edition, Elsevier BV, pp. 227–256, 2015.
• A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, J. Springer, “Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.,” Proceedings of the National Academy of Sciences, vol. 77, no. 7. pp. 3957–3961, 1980.
• J. A. Tobert, “Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors,” Nature Reviews Drug Discovery, vol. 2, no. 7. pp. 517–526, 2003.
• C. D. Furberg, B. Pitt, “Withdrawal of cerivastatin from the world market,” Trials, vol. 2, no. 205, pp. 1-3, 2001.
• T. B. Newman, “Carcinogenicity of Lipid-Lowering Drugs,” JAMA: The Journal of the American Medical Association, vol. 275, no. 1, p. 55, 1996.
• I. Karp, H. Behlouli, J. LeLorier, L. Pilote, “Statins and Cancer Risk,” The American Journal of Medicine, vol. 121, no. 4, pp. 302–309, 2008.
• G. Gajski, V. Garaj-Vrhovac, V. Oreščanin, “Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: Standard and Fpg-modified comet assay,” Toxicology and Applied Pharmacology, vol. 231, no. 1, pp. 85–93, 2008.
• R. L. Robison, W. Suter, R. H. Cox, “Carcinogenicity and Mutagenicity Studies with Fluvastatin, a New, Entirely Synthetic HMG-CoA Reductase Inhibitor,” Toxicological Sciences, vol. 23, no. 1, pp. 9–20, 1994.
• P. C. Orsolin, R. G. Silva-Oliveira, J. C. Nepomuceno, “Modulating effect of synthetic statins against damage induced by doxorubicin in somatic cells of Drosophila melanogaster,” Food and Chemical Toxicology, vol. 81. pp. 111–119, 2015.
• A. B. Raies, V. B. Bajic, “In silico toxicology: Computational methods for the prediction of chemical toxicity,” WIREs Computational Molecular Science, vol. 6, no. 2, pp. 147–172, 2016.
• G. J. Myatt, E. Ahlberg, Y. Akahori, D. Allen, A. Amberg, L. T. Anger, A. Aptula, S. Auerbach, L. Beilke, P. Bellion, R. Benigni, J. Bercu, E. D. Booth, D. Bower, A. Brigo, N. Burden, Z. Cammerer, M. T. D. Cronin, K. P. Cross, L. Custer, M. Dettwiler, K. Dobo, K. A. Ford, M. C. Fortin, S. E. Gad-McDonald, N. Gellatly, V. Gervais, K. P. Glover, S. Glowienke, J. Van Gompel, S. Gutsell, B. Hardy, J. S. Harvey, J. Hillegass, M. Honma, J. H. Hsieh, C. W. Hsu, K. Hughes, C. Johnson, R. Jolly, D. Jones, R. Kemper, M. O. Kenyon, M. T. Kim, N. L. Kruhlak, S. A. Kulkarni, K. Kümmerer, P. Leavitt, B. Majer, S. Masten, S. Miller, J. Moser, M. Mumtaz, W. Muster, L. Neilson, T. I. Oprea, G. Patlewicz, A. Paulino, E. Lo Piparo, M. Powley, D. P. Quigley, M. V. Reddy, A. N. Richarz, P. Ruiz, B. Schilter, R. Serafimova, W. Simpson, L. Stavitskaya, R. Stidl, D. Suarez-Rodriguez, D. T. Szabo, A. Teasdale, A. Trejo-Martin, J. P. Valentin, A. Vuorinen, B. A. Wall, P. Watts, A. T. White, J. Wichard, K. L. Witt, A. Woolley, D. Woolley, C. Zwickl, C. Hasselgren, “In silico toxicology protocols,” Regulatory Toxicology and Pharmacology, vol. 96, pp. 1–17, 2018.
• J. C. Dearden, “The History and Development of Quantitative Structure-Activity Relationships (QSARs),” Oncology: Breakthroughs in Research and Practice, ed. Information Resources Management Association, 2017, pp. 67–117.
• A. Danieli, E. Colombo, G. Raitano, A. Lombardo, A. Roncaglioni, A. Manganaro, A. Sommovigo, E. Carnesecchi, J.-L. C. M. Dorne, E. Benfenati, “The VEGA Tool to Check the Applicability Domain Gives Greater Confidence in the Prediction of In Silico Models,” International Journal of Molecular Sciences, vol. 24, no. 12, p. 9894, 2023.
• G. Patlewicz, N. Jeliazkova, R. J. Safford, A. P. Worth, B. Aleksiev, “An evaluation of the implementation of the Cramer classification scheme in the Toxtree software,” SAR and QSAR in Environmental Research, vol. 19, no. 6, pp. 495–524, 2008.
• C. Helma, “Lazy structure-activity relationships (lazar) for the prediction of rodent carcinogenicity and Salmonella mutagenicity,” Molecular Diversity, vol. 10, no. 2, pp. 147–158, 2006.
• T. M. Martin. (2016). User’s guide for T.E.S.T. (version 4.2) (Toxicity Estimation Software Tool) [Online]. Available: https://www.epa.gov/sites/production/files/2016-05/documents/600r16058.pdf
• D. Weininger, “SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules,” Journal of Chemical Information and Computer Sciences, vol. 28, no. 1, pp. 31–36, 1988.
• E. Benfenati, A. Manganaro, G. Gini, “VEGA-QSAR: AI inside a platform for predictive toxicology,” CEUR Workshop Proceedings, vol. 1107, Turin, Italy, CEUR-WS.org, 2013, pp. 21-28.
• S. Weaver, M. P. Gleeson, “The importance of the domain of applicability in QSAR modeling,” Journal of Molecular Graphics and Modelling, vol. 26, no. 8, pp. 1315–1326, 2008.
• E. Mombelli, A. Fernández, J. Cester, A. Roncaglioni. (2022). QMRF identifier (JRC Inventory): To be entered by JRC, QMRF Title: Mutagenicity (Ames test) CONSENSUS model-v. 1.0.4 [Online] Available: https://www.vegahub.eu/vegahub-dwn/qmrf/QMRF_MUTA_CONSENSUS.pdf
• G. M. Cramer, R. A. Ford, R. L. Hall, “Estimation of toxic hazard—A decision tree approach,” Food and Cosmetics Toxicology, vol. 16, no. 3, pp. 255–276, 1976.
• R. Benigni, “The Benigni/Bossa rulebase for mutagenicity and carcinogenicity-a module of Toxtree,” JRC scientific and technical reports, no. 63, 2008.
• U. S. Epa. (2020). User’s guide for test (version 5.1)(toxicity estimation software tool): A program to estimate toxicity from molecular structure [Online] Available: https://www.epa.gov/sites/default/files/2016-05/documents/600r16058.pdf
• A. Maunz, M. Gütlein, M. Rautenberg, D. Vorgrimmler, D. Gebele, C. Helma, “lazar: A modular predictive toxicology framework,” Frontiers in Pharmacology, vol. 4, 38, 2013.
• M. Van Bossuyt, G. Raitano, M. Honma, E. Van Hoeck, T. Vanhaecke, V. Rogiers, B. Mertens, E. Benfenati, “New QSAR models to predict chromosome damaging potential based on the in vivo micronucleus test,” Toxicology Letters, vol. 329. pp. 80–84, 2020.
• V. Ciaravino, M. L. Kropko, C. E. Rothwell, C. A. Hovey, J. C. Theiss, “The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia,” Mutation Research/Genetic Toxicology, vol. 343, no. 2–3, pp. 95–107, 1995.
• G. D. Friedman, E. D. Flick, N. Udaltsova, J. Chan Pharm D, C. P. Quesenberry Jr., L. A. Habel, “Screening statins for possible carcinogenic risk: Up to 9 years of follow‐up of 361 859 recipients,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 1, pp. 27–36, 2007.
• L. Björkhem-Bergman, J. Acimovic, U.-B. Torndal, P. Parini, L. C. Eriksson, “Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation,” Anticancer Research, vol. 30, no. 4, pp. 1105–1112, 2010.
• T.-Y. Yang, W.-M. Lin, C.-L. Lin, F.-C. Sung, C.-H. Kao, “Correlation between use of simvastatin and lovastatin and female lung cancer risk: A nationwide case-control study,” International Journal of Clinical Practice, vol. 69, no. 5, pp. 571–576, 2014.
• J. Acimovic, A. Lövgren-Sandblom, L. C. Eriksson, L. Björkhem-Bergman, “The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone,” Biochemical and Biophysical Research Communications, vol. 425, no. 2, pp. 348–352, 2012.
• L. M. Bjerre and J. LeLorier, “Do statins cause cancer? A meta-analysis of large randomized clinical trials,” The American Journal of Medicine, vol. 110, no. 9, pp. 716–723, 2001.
• A. A. Berber, M. Çelik, H. Aksoy, “Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin,” Drug and Chemical Toxicology, vol. 37, no. 3, pp. 316–321, 2013.